目的 探讨塞来昔布辅助治疗对老年肺癌患者炎性介质及肺功能的影响。方法 选取2014年1月—2016年6月在新乡市中心医院进行诊治的130例老年非小细胞肺癌患者，按治疗方法分为观察组、对照组，各65例，对照组使用培美曲塞联合顺铂进行化疗，观察组在对照组治疗的基础上给予塞来昔布辅助治疗，两组治疗观察3个月。比较两组的疗效及毒副反应情况，比较两组治疗前后的炎症因子、肺功能并随访到2017年12月，记录患者生存期。结果 治疗后观察组与对照组的总有效率分别为72.31%和53.80%，观察组显著高于对照组，差异有统计学意义（P<0.05）。治疗期间观察组的皮肤反应、骨髓抑制、消化道反应等毒副反应与对照组相比无显著差异，所有毒副反应对症处理后好转。观察组与对照组治疗后的血清IL-2与IL-6水平较治疗前显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；观察组更明显，组间差异有统计学意义（P<0.05）。治疗后两组的FEV1值较治疗前显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；观察组明显高于对照组，差异有统计学意义（P<0.05）。观察组与对照组的中位生存期分别为（13.44±2.12）个月和（11.94±3.19）个月，KM法分析显示观察组高于对照组，差异有统计学意义（P<0.05）。结论 塞来昔布辅助治疗老年肺癌患者能有效抑制炎性介质的释放，改善患者的肺功能，安全性好，从而有利于提高治疗效果与延长患者的生存期。
Objective To investigate the effects of celecoxib on the inflammatory mediators and lung function in elderly patients with lung cancer.Methods Selected 130 elderly patients with non-small cell lung cancer in our hospital for diagnosis and treatment from January 2014 to June 2016. All the cases were divided into observation group and control group with 65 cases in each group accorded to the different treatment methods. The control group received pemetrexed plus cisplatin for chemotherapy, the observation group was given celecoxib therapy based on the treatment in control group, two groups were observed for 3 months.Results The total effective rates of the observation group and the control group after treatment was 72.31% and 53.8% respectively, and the observation group was significantly higher than that of the control group (P<0.05). There were no significant difference in skin reaction, bone marrow suppression and digestive tract reaction comapred between the observation group and the control group during the treatment period. All the side effects were improved after symptomatic treatment. The level of serum IL-2 and IL-6 in the observation group and the control group were significantly lower than that before the treatment (P<0.05), and the observation group was also significantly lower than the control group after treatment (P<0.05). After treatment, the FEV1 value of the two groups was significantly higher than that before the treatment (P<0.05), and the FEV1 value of the observation group was significantly higher than that of the control group after treatment (P<0.05). The median survival time of the observation group and the control group were (13.44 ±2.12) months and (11.94 ±3.19) months respectively, KM analysis showed that the observation group was higher than the control group (P<0.05).Conclusions The celecoxib in the treatment of elderly patients with lung cancer can effectively inhibit the release of inflammatory mediators, improve the lung function and safety of patients, thereby improve the therapeutic effect and prolong the survival time of patients.